Morepen Laboratories secures fourth consecutive USFDA ‘NIL 483’ inspection

Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions

Morepen Labs lands record Rs. 825 crore global CDMO contract

This multi-year CDMO agreement involves significant, ongoing manufacturing for a global pharmaceutical major

Morepen Laboratories consolidated Q1 FY26 PAT lower at Rs. 11.40 Cr

Morepen Laboratories has reported total income of Rs. 429.64 crores during the period ended June 30, 2025

Morepen Laboratories reports Q4 FY25 consolidated PAT at Rs. 20.31 Cr

The company has posted net profit of Rs. 118.01 crores for the Financial Year ended March 31, 2025

Morepen Board proposed dividend after 23 years

Scores highest PAT of Rs. 118 crore in FY25

Dr. Morepen launches Rs. 499 annual multivitamin pack on Labour’s Day

Priced at just Rs. 499 for 1-year supply, this initiative is aligned with the vision of Health for All

Morepen to launch new fatty lever drug ‘Resmetirom’

Morepen to add 1,000 medical representatives

The company is targeting a Rs. 1,000 crore finished dosages business within the next five years

Morepen secures Loratadine approval for export to China

This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets

Morepen launches Empamore for diabetes care with affordable treatment

Empamore is poised to make a significant impact by offering high-quality treatment at an affordable price point, empowering millions of Indians to take control of their health